Suppr超能文献

病例报告:基于循环肿瘤DNA及胸腔积液沉淀细胞基因组DNA的系列基因检测指导下,对肺腺癌序贯联合应用埃克替尼、奥希替尼和克唑替尼的治疗

Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion.

作者信息

Miao Zhihua, Mu Tianhao, Liu Longying, Rao Jingjie, Jin Min, Wang Zhizheng, Wang Hui, Lu Chao, Gong Xiaolin, Zheng Dongcai, Zheng Daoming, Li Xin, Li Yingmei, Chen Shifu, Shu Xinhua

机构信息

Shangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.

HaploX Biotechnology, Shenzhen, China.

出版信息

Front Oncol. 2020 Oct 23;10:561341. doi: 10.3389/fonc.2020.561341. eCollection 2020.

Abstract

Precision medicine has been getting more attention in lung cancer treatment. Here, we report an unusual case of a 71-year-old Chinese male patient with poorly differentiated lung adenocarcinoma with lymph node metastasis. A 5 years' treatment history of this patient is reported. By serial genetic tests of circulating tumor DNA (ctDNA) from peripheral blood and sediment cell genomic DNA (PE-sDNA) from pleural effusion, a novel chronological combination treatment of icotinib, osimertinib, and crizotinib was adopted for the present genetic mutations, including exon 19 deletion, p.T790M, and amplification.

摘要

精准医学在肺癌治疗中越来越受到关注。在此,我们报告一例不同寻常的病例,一名71岁中国男性患者,患有低分化肺腺癌并伴有淋巴结转移。报告了该患者5年的治疗史。通过对来自外周血的循环肿瘤DNA(ctDNA)和来自胸腔积液的沉淀细胞基因组DNA(PE-sDNA)进行系列基因检测,针对包括外显子19缺失、p.T790M和扩增在内的当前基因突变,采用了埃克替尼、奥希替尼和克唑替尼的新型序贯联合治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25f7/7645070/9ce942c2a167/fonc-10-561341-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验